Inovio and advaccine receive regulatory allowance for two heterologous prime-boost clinical trials in china using ino-4800, inovio's covid-19 dna vaccine candidate

Plymouth meeting, pa. and suzhou, china, aug. 9, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced that it has received regulatory allowance for two clinical trials investigating heterologous boosting with ino-4800, its dna vaccine candidate for covid-19, through partner and trial-sponsor advaccine biopharmaceuticals suzhou co., ltd.
INO Ratings Summary
INO Quant Ranking